|
4D Pharma PLC - Leeds, England-based pharmaceutical company - Plans to conduct a phase II study to assess the safety of MRx0518 in combination with Bavencio. Says the study will be conducted in patients with unresectable locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. Says previous data about MRx0518 supports the potential of this combination to ‘significantly enhance and improve’ outcomes for patients, beyond treatment with Bavencio alone. Bavencio is an antibody medication for the treatment of urothelial carcinoma.
The study will primarily assess the effect of the combination on progression-free survival at six months. Plans to enrol 30 patients in the study. Adds that the study is being run in collaboration with peers such as Merck KGaA, and Pfizer Inc. Study sites are open for patient enrolment.
Current stock price: 33.98 pence, down 1.8%
12-month change: down 66%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
